c.US$2m multiplex diagnostic test contract win
Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
York, U.K. 10 November 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces a new contract win with an expected value of approximately US$2 million.
The Company has signed a Master Service Agreement (“MSA”) with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system. The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. The project is expected to take approximately 24 months via works orders under the MSA which are expected to total c. US$2 million. The project will be run from the Company’s Madison, Wisconsin facilities.
This contract win is another example of the strength of Abingdon Health’s CDMO offering which provides customers with comprehensive support to take an idea through to commercial success. The expansion of the Company’s Madison, Wisconsin, USA manufacturing capabilities, which is being accelerated following the recent £3.2m (net) fundraise and placing, satisfies the increasing demand from USA-based customers requiring development and manufacture. The Company is well placed to do this and has the benefit of being supported by the Group’s full CDMO and regulatory services offering from York, UK.
Abingdon Health’s brochure outlines the comprehensive support the Group provides to its international and UK customers.
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: “This contract award demonstrates the value of our comprehensive CDMO platform, and the benefit of our dual sites in USA and UK. It also illustrates the power and flexibility of lateral flow testing. The ability to measure multiple analytes semi-quantitatively, in a single test system, illustrates the utility of lateral flow testing beyond the more widely known single parameter qualitative ‘yes/no’ devices.
“The expertise and experience of Abingdon scientists and the full end-to-end CDMO service offering continues to resonate well with current and potential clients.”
Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman
Via Walbrook PR
Tom Hayes, CFO
Enquiries:
